Question explored with the scientific record
Is 25mg extra peganalin any danger to help stop panic attacks
No retrieved study tests Peganalin at any dose for panic attacks. The evidence base for this question is empty.
The retrieval found no study on Peganalin — not its safety, not its dosing, not its effect on panic. The records that came back cover unrelated drugs (betaxolol, reboxetine, lurasidone, propafenone, durvalumab) and panic mechanisms (lactate infusion, CO₂ challenge, CCK-4, flumazenil, isoproterenol, hypoxia in rats) [1][2][3][4][5][6][7][8][9][10]. None of them name Peganalin. None of them test an extra 25 mg of anything for stopping a panic attack.
Without a single study on the drug in question, there is no evidence to weigh. The question of danger cannot be answered from the literature that was retrieved. The question of benefit cannot be answered either. The retrieval simply did not find any study on Peganalin — not one on its pharmacology, its adverse effects, its interactions, or its use in panic disorder.
My call: no evidence was retrieved on Peganalin at any dose for panic attacks. The safety and efficacy of an extra 25 mg are unknown from this search. Confidence: not clear — the retrieval missed the entire topic.
Sources used 10
-
Differential reactivity to lactate infusions: The relative role of biological, psychological, and conditioning variables
This study investigates the differential reactivity to lactate infusions in patients with panic disorder compared to controls, revealing that while all patients experienced panic attacks, their symptoms and perceptions differed significantly from those of controls.
DOI: 10.1016/0006-3223(89)90200-x -
Betaxolol in Anxiety Disorders
This study investigates the therapeutic effects of betaxolol, a long-acting beta-adrenergic blocker, on patients with anxiety disorders, demonstrating significant improvements in anxiety symptoms and panic attacks within a short treatment period.
DOI: 10.3109/10401239809148813 -
Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers
This study investigates the effects of the cholecystokinin B receptor antagonist CI-988 on panic symptoms induced by cholecystokinin-tetrapeptide in healthy male volunteers, finding modest efficacy in reducing panic frequency and symptom intensity.
DOI: 10.1016/0006-3223(95)00081-X -
Comparison of the effects of cholecystokinin-tetrapeptide and carbon dioxide in healthy volunteers
In a non-blinded, head-to-head-provocation study in healthy volunteers, intravenous cholecystokinin-tetrapeptide (CCK-4, 25 μg) and inhaled 35% CO2 were compared for panicogenic effects; CCK-4 produced significantly more intense panic symptoms than CO2, but the incidence of pani…
DOI: 10.1016/0924-977x(91)90715-7 -
Oral propafenone therapy for children with arrhythmias: Efficacy and adverse effects in midterm follow-up
This study evaluates the efficacy and safety of oral propafenone therapy in 57 children with various arrhythmias, finding it effective particularly in those with normal hearts, while noting a low incidence of adverse effects.
DOI: 10.1016/0002-8703(91)90467-v -
Safety and efficacy of durvalumab (MEDI4736) in various solid tumors
This meta-analysis evaluates the safety and efficacy of durvalumab (MEDI4736), a PD-L1 inhibitor, in various solid tumors, finding it to be safe with manageable adverse effects and improved prognosis associated with higher PD-L1 expression.
DOI: 10.2147/dddt.s162214 -
Pharmacokinetic and Safety Evaluation of Lurasidone in Pediatric Patients with Psychiatric Disorders
This study evaluates the pharmacokinetics and safety of lurasidone in pediatric patients aged 6 to 17 with various psychiatric disorders, identifying a tolerated dose range and common adverse effects.
DOI: 10.1016/s0924-9338(15)30944-5 -
Minocycline engages microglia in the midbrain periaqueductal grey to attenuate hypoxia-triggered panic-like behaviour in rats
Hypoxic challenge (7% O2) evoked panic-like jumping and time-dependent microglial activation in the rat periaqueductal grey; minocycline, like alprazolam, reduced jumping and prevented dmPAG microglial remodelling, suggesting microglia as a panic-attack target.
DOI: 10.64898/2026.07.29.741424 -
QT interval variability in panic disorder patients after isoproterenol infusions
This study investigates the effects of sympathetic stimulation via isoproterenol infusions on QT interval variability in patients with panic disorder compared to normal controls, revealing that panic disorder patients exhibit greater QT variability which is further increased by …
DOI: 10.1017/s146114570100219x -
Effect of single doses of pindolol and d-fenfluramine on flumazenil-induced anxiety in panic disorder patients
A double-blind, randomized trial in treatment-free panic disorder patients tested whether acute elevation of serotonin via pindolol or d-fenfluramine would reduce flumazenil-induced anxiety/panic, finding no protective effect and suggesting flumazenil challenge may not model pan…
DOI: 10.1016/j.bbr.2017.11.002